AKP 020

Drug Profile

AKP 020

Alternative Names: AKP-020; BEOV

Latest Information Update: 20 Apr 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of British Columbia
  • Developer dgd Research
  • Class Antihyperglycaemics; Vanadium compounds
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 16 Feb 2009 Discontinued - Phase-II for Type-2 diabetes mellitus in USA (PO)
  • 26 Sep 2008 Akesis expands preclinical safety programme for AKP 020
  • 20 Jun 2008 Interim efficacy data from a phase IIa trial in Type-2 diabetes released by Akesis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top